Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates

Arbutus shares have added about 4.3% since the beginning of the year versus the S&P 500's gain of 7.1%. What's Next for Arbutus? While Arbutus has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Arbutus Biopharma (ABUS) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring i ...